Official AMFI data
Arthkar — Understand Money, Invest Smartly
quant

Quant Healthcare Fund

Sectoral / ThematicEquityVery High risk Rank 8 of 12

NAV · Direct-Growth

₹19.13-0.08-0.43%

As of 18 Nov 2026 · AMFI

NAV growth+18.4%
Nov ’25Nov ’26
Arthkar verdictMixed picture

Returns

Beats category

1Y, 3Y all ahead

Cost

High

1.62% vs 1.01% peers

Volatility

Above average

17.0% vs 16.1% cat (3Y)

Consistency

Steady

positive in 2 of 3 years

Beats its Sectoral / Thematic category on 1Y & 3Y — but has run more volatile than peers.

1Y return

+18.4%

+13.5 vs cat

3Y CAGR

+19.8%

+5.6 vs cat

5Y CAGR

—

AUM

₹416.6 Cr

fund size

Expense

1.62%

direct plan

Volatility 3Y

17.0%

▲ vs 16.1%

Go deeper on Quant Healthcare Fund

Two data-only views, computed from this fund's real NAV history — no projections.

In plain English

quant Healthcare Fund is a Sectoral / Thematic scheme from quant. The portfolio is ~99% in equities. 3-year CAGR: about 19.8%. Volatility is high — expect 30 %+ paper losses during major corrections. Worst historical drawdown: -25% in Mar 2025, recovered in 16 months. Wrong fit if you need this money in less than 7 years.

Auto-generated from holdings, returns and risk data. No paid placement, no copy-pasted boilerplate.

NAV history

Showing Direct · Growth · INF966L01CD0

NAV (Direct-Growth)

₹19.1288

Last 1Y

+18.36%

Nov 25Min ₹14.51 · Max ₹19.61 · 248 ptsNov 26

Drawdown stories

The crashes you should know about — and how long the fund took to recover.

Mar 2025

-25.2%

Peak ₹17.97 on 13 Sept 2024 → trough ₹13.44 on 3 Mar 2025 (6 months down).

Recovered in 16 months· 3 Jul 2026

Mar 2024

-11.1%

Peak ₹14.10 on 19 Feb 2024 → trough ₹12.53 on 13 Mar 2024 (1 months down).

Recovered in 2 months· 21 May 2024

Oct 2026

-10.2%

Peak ₹19.49 on 23 Sept 2026 → trough ₹17.51 on 23 Oct 2026 (1 months down).

Recovered in 1 months· 9 Nov 2026

Computed from the full NAV history. We show drawdowns deeper than 10%, sorted by depth.

Honesty score

A 1–5 grade on the dimensions other sites won't surface — expense bloat, AUM bloat, concentration, mandate compliance.

3

Honesty score

3 / 5

Watch a few items. Read the signal detail before investing.

  • Expense ratio

    1.62% — significantly above category norm.

  • AUM size

    ₹417 Cr.

  • Sector concentration

    Top 3 sectors = 67.0% — fairly concentrated.

Computed from expense ratio, AUM, sector concentration and SEBI mandate compliance. No paid review.

Performance

Returns for various periods, with category average and peer rank.

PeriodReturnsCategory avgRank
1W-1.93%-0.79%249/ 292
1M+5.36%+4.38%125/ 292
3M+1.85%+3.37%15/ 18
6M+13.43%+11.82%11/ 18
YTD+22.72%+5.12%15/ 273
1Y+18.36%+4.88%22/ 266
2Y+9.12%+6.93%73/ 218
3Y+19.81%+14.17%19/ 167
5Y—+15.54%—
7Y—+21.89%—
10Y—+15.63%—

Portfolio composition

Asset allocation

  • Equity99.26%
  • Cash0.74%

By market cap

  • Large cap18.38%
  • Mid cap57.91%
  • Small cap47.49%

Concentration

Holdings

27

Avg market cap

₹60.1K Cr

Top 10 stocks

64.12%

Top 5 stocks

41.69%

Top 3 sectors

67.04%

Top holdings

Top 15 positions by weight, latest disclosure.

#InstrumentSectorWeight
  • 2

    SMS Pharmaceuticals Ltd

    —10.42%
  • 3

    GlaxoSmithKline Pharmaceuticals Ltd

    —9.69%
  • 3

    GlaxoSmithKline Pharmaceuticals Ltd

    —9.69%
  • 4

    Divi's Laboratories Ltd.

    —9.63%
  • 4

    Divi's Laboratories Ltd.

    —9.63%
  • 5

    Zydus Lifesciences Ltd

    —9.39%
  • 5

    Zydus Lifesciences Ltd

    —9.39%
  • 6

    Glenmark Pharmaceuticals Ltd.

    —9.34%
  • 6

    Glenmark Pharmaceuticals Ltd.

    —9.34%
  • 3

    Anthem Biosciences Ltd

    —9.29%
  • 1

    Zydus Wellness Ltd

    —9.27%
  • 2

    Anthem Biosciences Ltd

    —9.17%
  • 4

    Aster DM Healthcare Ltd Ordinary Shares

    —9.16%
  • 7

    Strides Pharma Science Ltd

    —9.04%
  • 7

    Strides Pharma Science Ltd

    —9.04%

Fundamentals (vs category)

Portfolio-weighted ratios, compared with the category average.

MetricFundCategory avgDiff
  • P/E ratio32.8942.46-9.57
  • P/B ratio4.555.90-1.35
  • Price / Sales4.365.78-1.42
  • Price / Cash Flow24.5630.79-6.23
  • Dividend yield0.87%0.60%+0.27
  • Return on equity (ROE)—17.20%—

Risk metrics

Standard deviation, Sharpe, Sortino, Beta — all vs category average.

Metric1Y3Y5YCat 1YCat 3YCat 5Y
  • Standard deviation

    Volatility — lower means steadier returns.

    18.0818.19—14.8916.1115.49
  • Sharpe ratio

    Risk-adjusted return — higher is better.

    0.660.82—0.590.940.59
  • Sortino ratio

    Like Sharpe but only counts downside volatility.

    1.221.43—1.031.630.96
  • Beta

    1 = moves with the market. <1 = less volatile.

    0.990.99—0.960.960.95

Peers in Sectoral / Thematic

Other schemes in the same SEBI category, ranked by AUM.

Available plans & options

PlanOptionFull nameISIN

Click a plan to see its NAV and chart above. Direct plans have lower expense ratios than Regular — same portfolio, more of the return stays with you.